Pain in cancer survivors

British Journal of Pain

Volumn 8, Issue 4, 2014, Pages 139-153

  Brown, Matthew R D ^a,b   Ramirez, Juan D ^c   Farquhar Smith, Paul ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer pain; Late effect radiation toxicity; Pain management; Peripheral neuropathy; Persistent post surgical pain; Survivors

Indexed keywords

EID: 85006197419     PISSN: 20494637     EISSN: 20494645     Source Type: Journal    
DOI: 10.1177/2049463714542605     Document Type: Article

References (180)

1. Harrington CB, Hansen JA, Moskowitz M, et al. It’s not over when it’s over: long-term symptoms in cancer survivors - a systematic review. Int J Psychiatry Med 2010; 40(2): 163-181.
2. Van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels GA, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18(9): 1437-1449.
3. Amir Z, Neary D and Luker K. Cancer survivors’ views of work 3 years post diagnosis: a UK perspective. Eur J Oncol Nurs 2008; 12(3): 190-197.
4. Elliott J, Fallows A, Staetsky L, et al. The health and well-being of cancer survivors in the UK: findings from a population-based survey. Br J Cancer 2011; 105(Suppl. S1): S11-S20.
5. Krarup C and Crone C. Neurophysiological studies in malignant disease with particular reference to involvement of peripheral nerves. J Neurol 2002; 249: 651-661.
6. Cavaletti G and Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010; 6(12): 657-666.
7. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013; 63(6): 419-437.
8. Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006; 72(3): 151-169.
9. Speck RM, Samuel MD, Farrar JT, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 2013; 9(5): e234-e240.
10. Hausheer FH, Schilsky RL, Bain S, et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006; 33(1): 15-49.
11. Hogan QH. Labat lecture: the primary sensory neuron: where it is, what it does, and why it matters. Reg Anesth Pain Med 2010; 35(3): 306-311.
12. Djouhri L and Lawson SN. Abeta-fiber nociceptive primary afferent neurons: a review of incidence and properties in relation to other afferent A-fiber neurons in mammals. Brain Res Brain Res Rev 2004; 46(2): 131-145.
13. Shipton EA. Skin matters: identifying pain mechanisms and predicting treatment outcomes. Neurol Res Int 2013; 2013(5): 329-364.
14. McArthur JC, Stocks EA, Hauer P, et al. Epidermal nerve fiber density. Arch Neurol 1998; 55(12): 1513-1520.
15. Dubin AE and Patapoutian A. Nociceptors: the sensors of the pain pathway. J Clin Invest 2010; 120(11): 3760-3772.
16. Julius D and Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413(6852): 203-210.
17. Brown A. Axonal transport of membranous and non-membranous cargoes: a unified perspective. J Cell Biol 2003; 160(6): 817-821.
18. Millecamps S and Julien J-P. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 2013; 14(3): 161-176.
19. Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011; 10(3): 407-417.
20. LaPointe NE, Morfini G, Brady ST, et al. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013; 37: 231-239.
21. Ong V, Liem NLM, Schmid MA, et al. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia. J Pharmacol Exp Ther 2008; 324(2): 434-442.
22. Vandecandelaere A, Martin SR and Engelborghs Y. Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules. Biochem J 1997; 323(1): 189-196.
23. Grisold W, Cavaletti G and Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012; 14(Suppl. 4): iv45-iv54.
24. Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010; 17(7): 903-912, e44-e49.
25. Zheng H, Xiao WH and Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol 2012; 238(2): 225-234.
26. Han Y and Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol 2013; 4: 156.
27. Flatters SJL and Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122(3): 245-257.
28. Argyriou AA, Iconomou G and Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112(5): 1593-1599.
29. Kingery WS, Guo TZ, Poree LR, et al. Colchicine treatment of the sciatic nerve reduces neurogenic extravasation, but does not affect nociceptive thresholds or collateral sprouting in neuropathic or normal rats. Pain 1998; 74(1): 11-20.
30. Ferrier J, Pereira V, Busserolles J, et al. Emerging trends in understanding chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2013; 17(10): 364.
31. Bouillot S, Martin-Negrier ML, Vital A, et al. Peripheral neuropathy associated with mitochondrial disorders: 8 cases and review of the literature. J Peripher Nerv Syst 2002; 7(4): 213-220.
32. Galluzzi L, Blomgren K and Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 2009; 10(7): 481-494.
33. Xiao WH, Zheng H, Zheng FY, et al. Mitochondrialabnormality in sensory, but not motor, axons in pacli-taxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011; 199(514): 461-469.
34. Zheng H, Xiao WH and Bennett GJ. Functionaldeficits in peripheral nerve mitochondria in rats withpaclitaxeland oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011; 232(2): 154-161.
35. Xiao WH and Bennett GJ. Chemotherapy-evokedneuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 2008; 135(3): 262-270.
36. Janes K, Doyle T, Bryant L, et al. Bioenergetic defi-cits in peripheral nerve sensory axons during che-motherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. Pain 2013; 154(11): 2432-2440.
37. Podratz JL, Knight AM, Ta LE, et al. Cisplatin inducedmitochondrial DNA damage in dorsal root ganglionneurons. Neurobiol Dis 2011; 41(3): 661-668.
38. Jaggi AS and Singh N. Mechanisms in cancer-che-motherapeutic drugs-induced peripheral neuropathy. Toxicology 2012; 291(1-3): 1-9.
39. Farquhar-Smith P. Chemotherapy-induced neuro-pathic pain. Curr Opin Support Palliat Care 2011; 5(1):1-7.
40. Virmani A, Gaetini F, Imam S, et al. Possible mecha-nism for the neuroprotective effects of L-carnitineon methamphetamine-evoked neurotoxicity. Ann N Y Acad Sci 2003; 993(1): 197-207.
41. Scholz J, Broom DC, Youn D-H, et al. Blocking cas-pase activity prevents transsynaptic neuronal apoptosisand the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 2005; 25(32): 7317-7323.
42. Jin HW, Flatters SJL, Xiao WH, et al. Prevention ofpaclitaxel-evoked painful peripheral neuropathy byacetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008; 210(1): 229-237.
43. Benn SC and Woolf CJ. Adult neuron survival strate-gies slamming on the brakes. Nat Rev Neurosci 2004; 5(9): 686-700.
44. Calvo M, Dawes JM and Bennett DLH. The role of theimmune system in the generation of neuropathic pain. Lancet Neurol 2012; 11(7): 629-642.
45. Calvo M and Bennett DLH. The mechanisms ofmicrogliosis and pain following peripheral nerve injury. Exp Neurol 2012; 234(2): 271-282.
46. Calvo M, Zhu N, Tsantoulas C, et al. Neuregulin-ErbB signaling promotes microglial proliferationand chemotaxis contributing to microgliosis and pain after peripheral nerve injury. J Neurosci 2010; 30(15): 5437-5450.
47. Marchand F, Perretti M and McMahon SB. Role ofthe immune system in chronic pain. Nat Rev Neurosci 2005; 6(7): 521-532.
48. Warwick RA and Hanani M. The contribution of sat-ellite glial cells to chemotherapy-induced neuropathicpain. Eur J Pain 2013; 17(4): 571-580.
49. Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel administration in the rat inducesa peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007; 203(1): 42-54.
50. Peters CM, Jimenez-Andrade JM, Kuskowski MA, et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007; 1168(612): 46-59.
51. Cavaletti G, Pezzoni G, Pisano C, et al. Cisplatin-induced peripheral neurotoxicity in rats reduces thecirculating levels of nerve growth factor. Neurosci Lett 2002; 322(2): 103-106.
52. Wang X-M, Lehky TJ, Brell JM, et al. Discoveringcytokines as targets for chemotherapy-induced painfulperipheral neuropathy. Cytokine 2012; 59(1): 3-9.
53. Alaedini A, Xiang Z, Kim H, et al. Up-regulation ofapoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Exp Neurol 2008; 210(2): 368-374.
54. Romani N, Brunner PM and Stingl G. Changing viewsof the role of Langerhans cells. J Invest Dermatol 2012;132(3 Pt 2): 872-881.
55. Dauch JR, Bender DE, Luna-Wong LA, et al. Neu-rogenic factor-induced Langerhans cell activation indiabetic mice with mechanical allodynia. J Neuroinflammation 2013; 10: 64.
56. Casanova-Molla J, Morales M, Planas-Rigol E, et al. Epidermal Langerhans cells in small fiber neuropa-thies. Pain 2012; 153(5): 982-989.
57. Chiorazzi A, Canta A, Meregalli C, et al. Antibodyagainst tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model. Anticancer Res 2013; 33(12): 5453-5459.
58. Bujalska M, Tatarkiewicz J and Gumułka SW. Effectof bradykinin receptor antagonists on vincristineandstreptozotocin-induced hyperalgesia in a rat model of chemotherapy-induced and diabetic neuropathy. Pharmacology 2008; 81(2): 158-163.
59. Descoeur J, Pereira V, Pizzoccaro A, et al. Oxaliplatin-induced cold hypersensitivity is due to remodellingof ion channel expression in nociceptors. EMBO Mol Med 2011; 3(5): 266-278.
60. Mihara Y, Egashira N, Sada H, et al. Involvement ofspinal NR2B-containing NMDA receptors in oxali-platin-induced mechanical allodynia in rats. Mol Pain 2011; 7(1): 8.
61. Alessandri-Haber N, Dina OA, Yeh JJ, et al. Transientreceptor potential vanilloid 4 is essential in chemo-therapy-induced neuropathic pain in the rat. J Neurosci 2004; 24(18): 4444-4452.
62. Puntambekar P, Mukherjea D, Jajoo S, et al. Essentialrole of Rac1/NADPH oxidase in nerve growth factorinduction of TRPV1 expression. J Neurochem 2005; 95(6): 1689-1703.
63. Gutiérrez-Gutiérrez G, Sereno M, Miralles A, et al. Chemotherapy-induced peripheral neuropathy: clini-cal features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 2010; 12(2): 81-91.
64. Verstappen CCP, Heimans JJ, Hoekman K, et al. Neu-rotoxic complications of chemotherapy in patientswith cancer: clinical signs and optimal management. Drugs 2003; 63(15): 1549-1563.
65. Wolf S, Barton D, Kottschade L, et al. Chemother-apy-induced peripheral neuropathy: prevention andtreatment strategies. Eur J Cancer 2008; 44(11): 1507-1515.
66. Van den Bent MJ. Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor. ClinCancer Res 2005; 11(5): 1691-1693.
67. Quasthoff S and Hartung HP. Chemotherapy-inducedperipheral neuropathy. J Neurol 2002; 249(1): 9-17.
68. Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013; 31(21): 2699-2707.
69. Chaudhary UB and Haldas JR. Long-term complica-tions of chemotherapy for germ cell tumours. Drugs 2003; 63(15): 1565-1577.
70. Mantyh PW. Cancer pain and its impact on diagno-sis, survival and quality of life. Nat Rev Neurosci 2006;7(10): 797-809.
71. Stubblefield MD, McNeely ML, Alfano CM, et al. Aprospective surveillance model for physical rehabilita-tion of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer 2012; 118(Suppl. 8): 2250-60.
72. Postma TJ and Heimans JJ. Review: grading ofchemotherapy-induced peripheral neuropathy. AnnOncol 2000; 11: 509-513.
73. Miller AB, Hoogstraten B, Staquet M, et al. Report-ing results of cancer treatment. Cancer 1981; 47(1):207-214.
74. Cleeland CS, Farrar JT and Hausheer FH. Assessmentof cancer-related neuropathy and neuropathic pain.Oncologist 2010; 15(Suppl. 2): 13-18.
75. Postma TJ. Original article: pitfalls in grading severityof chemotherapy-induced peripheral neuropathy. AnnOncol 1998; 9: 739-744.
76. Cavaletti G, Cornblath DR, Merkies ISJ, et al. Thechemotherapy-induced peripheral neuropathy out-come measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013; 24(2): 454-462.
77. Binda D, Vanhoutte EK, Cavaletti G, et al. Rasch-builtOverall Disability Scale for patients with chemother-apy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer 2013; 49(13): 2910-2918.
78. Velasco R, Bruna J, Briani C, et al. Early predictors ofoxaliplatin-induced cumulative neuropathy in colorec-tal cancer patients. J Neurol Neurosurg Psychiatry 2014; 85(4): 392-398.
79. Haanpää M, Attal N, Backonja M, et al. NeuPSIGguidelines on neuropathic pain assessment. Pain 2011;152(1): 14-27.
80. Forsyth PA, Balmaceda C, Peterson K, et al. Prospec-tive study of paclitaxel-induced peripheral neuropathywith quantitative sensory testing. J Neurooncol 1997; 35(1): 47-53.
81. Cavaletti G, Bogliun G, Marzorati L, et al. Early pre-dictors of peripheral neurotoxicity in cisplatin andpaclitaxel combination chemotherapy. Ann Oncol 2004; 15(9): 1439-1442.
82. Lauria G and Devigili G. Skin biopsy as a diagnostictool in peripheral neuropathy. Nat Clin Pract Neurol 2007; 3(10): 546-557.
83. Üçeyler N, Zeller D, Kahn A-K, et al. Small fibrepathology in patients with fibromyalgia syndrome. Brain 2013; 136(Pt 6): 1857-1867.
84. Krøigård T, Schrøder HD, Qvortrup C, et al. Charac-terization and diagnostic evaluation of chronic poly-neuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol 2014; 21(4): 623-629.
85. Delaney G, Jacob S, Featherstone C, et al. The roleof radiotherapy in cancer treatment: estimating opti-mal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104(6): 1129-1137.
86. Hubenak JR, Zhang Q, Branch CD, et al. Mechanismsof injury to normal tissue after radiotherapy: a review. Plast Reconstr Surg 2014; 133(1): 49e-56e.
87. Jackson SP and Bartek J. The DNA-damage responsein human biology and disease. Nature 2009; 461(7267):1071-1078.
88. Begg AC, Stewart FA and Vens C. Strategies toimprove radiotherapy with targeted drugs. Nat RevCancer 2011; 11(4): 239-253.
89. Rzeszowska-Wolny J, PrzybyszewskiWM andWidel M.Ionizing radiation-induced bystander effects, potentialtargets for modulation of radiotherapy. Eur J Pharmacol 2009; 625(1-3): 156-164.
90. Blyth BJ and Sykes PJ. Radiation-induced bystandereffects: what are they, and how relevant are they tohuman radiation exposures? Radiat Res 2011; 176(2): 139-157.
91. Fogarty GB, Muddle R, Sprung CN, et al. Unexpect-edly severe acute radiotherapy side effects are asso-ciated with single nucleotide polymorphisms of the melanocortin-1 receptor. Int J Radiat Oncol Biol Phys 2010; 77(5): 1486-1492.
92. Begg AC. Can the severity of normal tissue damageafter radiation therapy be predicted? PLoS Med 2006; 3(10): e440.
93. Bentzen SM. Preventing or reducing late side effectsof radiation therapy: radiobiology meets molecularpathology. Nat Rev Cancer 2006; 6(9): 702-713.
94. Gami B, Harrington K, Blake P, et al. How patientsmanage gastrointestinal symptoms after pelvic radio-therapy. Aliment Pharmacol Ther 2003; 18(10): 987-994.
95. Eifel PJ, Levenback C, Wharton JT, et al. Time courseand incidence of late complications in patients treatedwith radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32(5): 1289-1300.
96. Bye A, Ha J, Hjermstad M, et al. Health-related qual-ity of life and occurrence of intestinal side effects afterpelvic radiotherapy: evaluation of long-term effects of diagnosis and treatment. Acta Oncol 2000; 39(2): 173-180.
97. Birgisson H, Påhlman L, Gunnarsson U, et al. Adverseeffects of preoperative radiation therapy for rectal can-cer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005; 23(34): 8697-8705.
98. Gervaz P, Morel P and Vozenin-Brotons M-C. Molec-ular aspects of intestinal radiation-induced fibrosis. Curr Mol Med 2009; 9(3): 273-280.
99. Yarnold J and Brotons MCV. Pathogenetic mecha-nisms in radiation fibrosis. Radiother Oncol 2010; 97(1):149-161.
100. Shadad AK, Sullivan FJ, Martin JD, et al. Gastroin-testinal radiation injury: symptoms, risk factors andmechanisms. World J Gastroenterol 2013; 19(2): 185-198.
101. Hauer-Jensen M, Wang J and Denham J. Bowel injury:current and evolving management strategies. SeminRadiat Oncol 2003; 13(3): 358-371.
102. Hamama S, Delanian S, Monceau V, et al. Therapeuticmanagement of intestinal fibrosis induced by radiationtherapy: from molecular profiling to new intervention strategies et vice et versa. Fibrogenesis Tissue Repair 2012; 5(Suppl. 1): S13.
103. Gothard L, Cornes P, Brooker S, et al. Phase II studyof vitamin E and pentoxifylline in patients with lateside effects of pelvic radiotherapy. Radiother Oncol 2005; 75(3): 334-341.
104. Delanian S, Balla-Mekias S and Lefaix JL. Strikingregression of chronic radiotherapy damage in a clinicaltrial of combined pentoxifylline and tocopherol. J Clin Oncol 1999; 17(10): 3283-3290.
105. Hamama S, Gilbert-Sirieix M, Vozenin M-C, et al. Radiation-induced enteropathy: molecular basis ofpentoxifylline-vitamin E anti-fibrotic effect involved TGF-β1 cascade inhibition. Radiother Oncol 2012;105(3): 305-312.
106. Delanian S, Porcher R, Balla-Mekias S, et al. Ran-domized, placebo-controlled trial of combined pent-oxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003; 21(13): 2545-2550.
107. Chiao TB and Lee AJ. Role of pentoxifylline and vita-min E in attenuation of radiation-induced fibrosis. Ann Pharmacother 2005; 39(3): 516-522.
108. Chen AM, Hall WH, Li J, et al. Brachial plexus-asso-ciated neuropathy after high-dose radiation therapyfor head-and-neck cancer. Int J Radiat Oncol Biol Phys 2012; 84(1): 165-169.
109. Eblan MJ, Corradetti MN, Lukens JN, et al. Brachialplexopathy in apical non-small cell lung cancer treatedwith definitive radiation: dosimetric analysis and clinical implications. Int J Radiat Oncol Biol Phys 2013; 85(1): 175-181.
110. Gosk J, Rutowski R, Reichert P, et al. Radiation-inducedbrachial plexus neuropathy - aetiopathogenesis, riskfactors, differential diagnostics, symptoms and treatment. Folia Neuropathol 2007; 45(1): 26-30.
111. Delanian S, Lefaix J and Pradat P. Radiation-inducedneuropathy in cancer survivors. Radiother Oncol 2012;105(3): 273-282.
112. Johansson S. Radiation induced brachial plexopathies. Acta Oncol 2006; 45(3): 253-257.
113. Gałecki J, Hicer-Grzenkowicz J, Grudzień-Kowalska M, et al. Radiation-induced brachial plexopathy andhypofractionated regimens in adjuvant irradiation of patients with breast cancer - a review. Acta Oncol 2006; 45(3): 280-284.
114. Olsen NK, Pfeiffer P, Johannsen L, et al. Radiation-induced brachial plexopathy: neurological follow-up in161 recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys 1993; 26(1): 43-49.
115. Fathers E, Thrush D, Huson SM, et al. Radiation-induced brachial plexopathy in women treated forcarcinoma of the breast. Clin Rehabil 2002; 16(2): 160-165.
116. Behnke NK, Crosby SN, Stutz CM, et al. Periscapularamputation as treatment for brachial plexopathy sec-ondary to recurrent breast carcinoma: a case series and review of the literature. Eur J Surg Oncol 2013; 39(12): 1325-1331.
117. Qayyum A, MacVicar AD, Padhani AR, et al. Symp-tomatic brachial plexopathy following treatment forbreast cancer: utility of MR imaging with surface-coil techniques1. Radiology 2000; 214(3): 837-842.
118. Macrae WA. Chronic post-surgical pain: 10 years on.Br J Anaesth 2008; 101(1): 77-86.
119. Kehlet H, Jensen TS and Woolf CJ. Persistent postsur-gical pain: risk factors and prevention. Lancet 2006;367(9522): 1618-1625.
120. Katz J and Seltzer Z. Transition from acute to chronicpostsurgical pain: risk factors and protective factors. Expert Rev Neurother 2009; 9(5): 723-744.
121. Bruce J and Quinlan J. Chronic post surgical pain. BrJ Pain 2011; 5(3): 23-29.
122. Cregg R, Anwar S and Farquhar-Smith P. Persistentpostsurgical pain. Curr Opin Support Palliat Care 2013;7(2): 144-152.
123. Høimyr H, von Sperling ML, Rokkones KA, et al. Persistent pain after surgery for cutaneous melanoma. Clin J Pain 2012; 28(2): 149-156.
124. Haroutiunian S, Nikolajsen L, Finnerup NB, et al. Theneuropathic component in persistent postsurgical pain:a systematic literature review. Pain 2013; 154(1): 95-102.
125. Høimyr H, Rokkones KA, von Sperling ML, et al. Persistent pain after lymph node excision in patientswith malignant melanoma is neuropathic. Pain 2011; 152(12): 2721-2728.
126. Guastella V, Mick G, Soriano C, et al. A prospectivestudy of neuropathic pain induced by thoracotomy:incidence, clinical description, and diagnosis. Pain 2011; 152(1): 74-81.
127. Kalso E. IV. Persistent post-surgery pain: researchagenda for mechanisms, prevention, and treatment. BrJ Anaesth 2013; 111(1): 9-12.
128. Asahina a Hosoi J, Grabbe S and Granstein RD. Modu-lation of Langerhans cell function by epidermal nerves. J Allergy Clin Immunol 1995; 96(6 Pt 2): 1178-1182.
129. Hou Q, Barr T, Gee L, et al. Keratinocyte expressionof calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms. Pain 2011; 152(9): 2036-2051.
130. Dubner R and Ruda MA. Activity-dependent neuro-nal plasticity following tissue injury and inflammation. Trends Neurosci 1992; 15(3): 96-103.
131. Reichling DB, Green PG and Levine JD. The funda-mental unit of pain is the cell. Pain 2013; 154(Suppl 1): S2-S9.
132. Ji RR and Woolf CJ. Neuronal plasticity and signaltransduction in nociceptive neurons: implications forthe initiation and maintenance of pathological pain. Neurobiol Dis 2001; 8(1): 1-10.
133. Woolf CJ. Central sensitization: implications for thediagnosis and treatment of pain. Pain 2011; 152(Suppl 3): S2-S15.
134. Andersen KG and Kehlet H. Persistent pain afterbreast cancer treatment: a critical review of risk fac-tors and strategies for prevention. J Pain 2011; 12(7): 725-746.
135. Vilholm OJ, Cold S, Rasmussen L, et al. The postmas-tectomy pain syndrome: an epidemiological study onthe prevalence of chronic pain after surgery for breast cancer. Br J Cancer 2008; 99(4): 604-610.
136. Peng Z, Li H, Zhang C, et al. A retrospective study ofchronic post-surgical pain following thoracic surgery:prevalence, risk factors, incidence of neuropathic component, and impact on qualify of life. PLoS One 2014; 9(2): e90014.
137. Peters ML, Sommer M, de Rijke JM, et al. Somaticand psychologic predictors of long-term unfavorableoutcome after surgical intervention. Ann Surg 2007; 245(3): 487-494.
138. Perkins FM and Kehlet H. Chronic pain as an out-come of surgery. A review of predictive factors. Anes-thesiology 2000; 93(4): 1123-1133.
139. Callesen T, Bech K and Kehlet H. Prospective study ofchronic pain after groin hernia repair. Br J Surg 1999;86(12): 1528-1531.
140. Tsirline VB, Colavita PD, Belyansky I, et al. Preop-erative pain is the strongest predictor of postoperativepain and diminished quality of life after ventral hernia repair. Am Surg 2013; 79(8): 829-836.
141. Bruce J, Thornton AJ, Scott NW, et al. Chronic preop-erative pain and psychological robustness predict acutepostoperative pain outcomes after surgery for breast cancer. Br J Cancer 2012; 107(6): 937-946.
142. Pinto PR, McIntyre T, Ferrero R, et al. Risk factors formoderate and severe persistent pain in patients under-going total knee and hip arthroplasty: a prospective predictive study. PLoS One 2013; 8(9): e73917.
143. Liu SS, Buvanendran A, Rathmell JP, et al. A cross-sectional survey on prevalence and risk factors for persistent postsurgical pain 1 year after total hip and knee replacement. Reg Anesth Pain Med 2012; 37(4): 415-422.
144. Bruce J, Drury N, Poobalan A, et al. The prevalenceof chronic chest and leg pain following cardiac sur-gery: a historical cohort study. Pain 2003; 104(1-2): 265-273.
145. Belfer I, Schreiber KL, Shaffer JR, et al. Persistentpostmastectomy pain in breast cancer survivors: analy-sis of clinical, demographic, and psychosocial factors. J Pain 2013; 14(10): 1185-1195.
146. Theunissen M, Peters ML, Bruce J, et al. Preoperativeanxiety and catastrophizing: a systematic review andmeta-analysis of the association with chronic postsurgical pain. Clin J Pain 2012; 28(9): 819-841.
147. Hinrichs-Rocker A, Schulz K, Järvinen I, et al. Psy-chosocial predictors and correlates for chronic post-surgical pain (CPSP) - a systematic review. Eur J Pain 2009; 13(7): 719-730.
148. Masselin-Dubois A, Attal N, Fletcher D, et al. Arepsychological predictors of chronic postsurgical paindependent on the surgical model? A comparison of total knee arthroplasty and breast surgery for cancer. J Pain 2013; 14(8): 854-864.
149. Mejdahl MK, Andersen KG, Gärtner R, et al. Per-sistent pain and sensory disturbances after treatmentfor breast cancer: six year nationwide follow-up study. BMJ 2013; 346: f1865.
150. Andersen KG, Jensen M-B, Kehlet H, et al. Persistentpain, sensory disturbances and functional impairmentafter adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. Acta Oncol 2012; 51(8): 1036-1044.
151. Barabas ME and Stucky CL. TRPV1, but not TRPA1,in primary sensory neurons contributes to cutaneousincision-mediated hypersensitivity. Mol Pain 2013; 9(1): 9.
152. Liu SS, Buvanendran A, Rathmell JP, et al. Predic-tors for moderate to severe acute postoperative painafter total hip and knee replacement. Int Orthop 2012; 36(11): 2261-2267.
153. Werner MU, Duun P and Kehlet H. Prediction of post-operative pain by preoperative nociceptive responsesto heat stimulation. Anesthesiology 2004; 100(1): 115-119, discussion 5A.
154. Strulov L, Zimmer EZ, Granot M, et al. Pain catastro-phizing, response to experimental heat stimuli, andpost-cesarean section pain. J Pain 2007; 8(3): 273-279.
155. Lundblad H, Kreicbergs A and Jansson KA. Predic-tion of persistent pain after total knee replacement forosteoarthritis. J Bone Joint Surg Br 2008; 90(2): 166-171.
156. Yarnitsky D, Crispel Y, Eisenberg E, et al. Prediction ofchronic post-operative pain: pre-operative DNIC test-ing identifies patients at risk. Pain 2008; 138(1): 22-28.
157. Werner MU, Mjöbo HN, Nielsen PR, et al. Predictionof postoperative pain: a systematic review of predictive experimental pain studies. Anesthesiology 2010; 112(6): 1494-1502.
158. Buvanendran A, Kroin JS, Della Valle CJ, et al. Perioperative oral pregabalin reduces chronicpain after total knee arthroplasty: a prospective, randomized, controlled trial. Anesth Analg 2010; 110(1): 199-207.
159. Clarke H, Bonin RP, Orser BA, et al. The prevention ofchronic postsurgical pain using gabapentin and prega-balin: a combined systematic review and meta-analysis. Anesth Analg 2012; 115(2): 428-442.
160. Chaparro LE, Smith SA, Moore RA, et al. Pharma-cotherapy for the prevention of chronic pain aftersurgery in adults. Cochrane Database Syst Rev 2013; 7(7): CD008307.
161. Andreae MH and Andreae DA. Regional anaesthesiato prevent chronic pain after surgery: a Cochrane sys-tematic review and meta-analysis. Br J Anaesth 2013; 111(5): 711-720.
162. Riddle DL, Keefe FJ, Nay WT, et al. Pain coping skillstraining for patients with elevated pain catastrophiz-ing who are scheduled for knee arthroplasty: a quasi-experimental study. Arch Phys Med Rehabil 2011; 92(6): 859-865.
163. Dworkin RH, McDermott MP and Raja SN. Prevent-ing chronic postsurgical pain: how much of a differ-ence makes a difference? Anesthesiology 2010; 112(3): 516-518.
164. Gilron I and Kehlet H. Prevention of chronic pain aftersurgery: new insights for future research and patientcare. Can J Anaesth. 2014; 61(2): 101-111.
165. Kalso E, Tasmuth T and Neuvonen PJ. Amitriptylineeffectively relieves neuropathic pain following treat-ment of breast cancer. Pain 1996; 64(2): 293-302.
166. Tasmuth T, Härtel B and Kalso E. Venlafaxine in neu-ropathic pain following treatment of breast cancer. Eur J Pain 2002; 6(1): 17-24.
167. Garzón-Rodríguez C, Casals Merchan M, Cal-sina-Berna A, et al. Lidocaine 5% patches as aneffective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer 2013; 21(11): 3153-3158.
168. Longson D. Neuropathic pain - pharmacological man-agement: the pharmacological management of neuropathicpain in adults in non-specialist settings. NICE clinical guideline 173, November 2 London: National Institute for Health and Care Excellence.
169. Stubblefield MD and Custodio CM. Upper-extremitypain disorders in breast cancer. Arch Phys Med Rehabil 2006; 87(3 Suppl. 1): S96-S99, quiz S100-S101.
170. Denham JW and Hauer-Jensen M. Radiation inducedbowel injury: a neglected problem. Lancet 2013; 382(9910): 2046-2047.
171. Andreyev HJN, Benton BE, Lalji A, et al. Algorithm- based management of patients with gastrointestinalsymptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet 2013; 382(9910): 2084-2092.
172. Wesselmann U, Baranowski AP, Börjesson M, et al. Emerging therapies and novel approaches to visceralpain. Drug Discov Today Ther Strateg 2009; 6(3): 89-95.
173. Davis MP. Drug management of visceral pain: con-cepts from basic research. Pain Res Treat 2012; 2012: 265605.
174. Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life amongpatients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309(13): 1359-1367.
175. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-inducedperipheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 2014; 32(18): 1941-1967.
176. Anand P and Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms ofaction of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107(4): 490-502.
177. De Leon-Casasola O. Multimodal approaches to the management of neuropathic pain: the role of topicalanalgesia. J Pain Symptom Manage 2007; 33(3): 356-364.
178. Gaudioso C, Hao J, Martin-Eauclaire M-F, et al. Menthol pain relief through cumulative inactivationof voltage-gated sodium channels. Pain 2012; 153(2): 473-484.
179. Nieto FR, Entrena JM, Cendán CM, et al. Tetrodotoxin inhibits the development and expression of neu-ropathic pain induced by paclitaxel in mice. Pain 2008; 137(3): 520-531.
180. Rahn EJ, Deng L, Thakur GA, et al. Prophylactic cannabinoid administration blocks the development ofpaclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Mol Pain 2014; 10(1): 27.